TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10

Future Oncology · Published 2026-07-27 · DOI 10.1080/14796694.2026.2701483

Free full text

Authors (16)

Hope S. Rugo, Peter Schmid, Javier Cortes, Toshimi Takano, Peter A. Fasching, Yeon Hee Park, Giampaolo Bianchini, Sandra Ximena Franco, Cynthia Villarreal-Garza, Olivier Tredan, Yongmei Yin, Romualdo Barroso-Sousa, Xuan Peng, Usha Malhotra, Karen Lisa Smith, Aditya Bardia

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Rugo, H., Schmid, P., Cortes, J., et al. (2026). TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future Oncology. https://doi.org/10.1080/14796694.2026.2701483

Related articles

• Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer · Breast Cancer: Basic and Clinical Research · 2023 · Cites or is cited by this article
• New Treatment Approaches for Triple-Negative Breast Cancer · American Society of Clinical Oncology Educational Book · 2025 · Cites or is cited by this article
• Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · Future Oncology · 2026 · Same journal
• Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · Future Oncology · 2026 · Same journal
• Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · Future Oncology · 2026 · Same journal
• Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · Future Oncology · 2026 · Same journal
• Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · Future Oncology · 2026 · Same journal
• IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · Future Oncology · 2026 · Same journal
• Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · Future Oncology · 2026 · Same journal
• Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · Future Oncology · 2026 · Same journal